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New Class of HIV Integrase Inhibitors
that Block Viral Replication in Cell Culture
Introduction
Replication of the human immunodeficiency virus type 1
Christophe Pannecouque,1,4 Wim Pluymers,1,4
Be´ne´dicte Van Maele,1 Victor Tetz,2
Peter Cherepanov,1 Erik De Clercq,1
(HIV-1) can be drastically reduced in infected patientsMyriam Witvrouw,1 and Zeger Debyser1,3
by combining potent antiviral drugs targeted at multiple1Rega Institute for Medical Research
viral targets [1]. Drugs that have been formally approvedKULeuven
for the treatment of HIV-infected patients belong to theMinderbroedersstraat 10
class of reverse transcriptase (RT) inhibitors (nucleo-B-3000 Leuven
sides/nucleotides and nonnucleosides) or protease in-Belgium
hibitors. Multiple-drug combination regimens can re-2 Department of Microbiology, Virology
duce viral load below the detection limit of the mostand Immunology
sensitive tests [2]. Nevertheless, low-level ongoing repli-Saint-Petersburg Pavlov State Medical University
cation has been shown to occur, possibly in sanctuary6/8 Leo Tolstoy Street
sites, leading to the emergence of drug-resistant strains.197089 Saint-Petersburg
Moreover, HIV can develop resistance to most if not allRussia
currently used antiviral drugs.
In an effort to improve combination therapy, to reduce
viral replication even further, and to cope with virus
strains that are resistant to multiple drugs, we initiatedSummary
a search for effective inhibitors of the third viral enzyme,
the integrase. This enzyme is responsible for insertingBackground: To improve the existing combination ther-
the viral cDNA into the host cell chromosome, an essen-apies of infection with the human immunodeficiency vi-
tial step in the replication of the virus [3, 4]. Since norus (HIV) and to cope with virus strains that are resistant
human counterpart of the enzyme is known, there isto multiple drugs, we initiated a search for effective
considerable interest in developing effective and selec-inhibitors of HIV integrase, the enzyme responsible for
tive inhibitors of the HIV integration process [5]. Integra-inserting the viral cDNA into the host cell chromosome.
tion is carried out by the integrase (IN), a protein of 32Results: We have now identified a series of 5H-
kDa encoded at the 3 end of the pol gene [6]. Thepyrano[2,3-d:-6,5-d]dipyrimidines that block the repli-
enzyme is produced by protease-mediated cleavage of
cation of various strains of HIV-1 and HIV-2. The most
the gag-pol precursor during virion maturation. Integ-
potent congener, 5-(4-nitrophenyl)-2,8-dithiol-4,6-dihy-
rase recognizes specific sequences in the long terminal
droxy-5H-pyrano[2,3-d:-6,5-d]dipyrimidine (V-165), in-
repeat (LTR) elements of the viral cDNA. The terminal
hibited the replication of HIV-1(IIIB) in MT-4 cells at a 15 bp of the LTR are necessary and sufficient for site-
50% effective concentration (EC50) of 8.9 M, which is specific cleavage and integration. The highly conserved
14-fold below its cytotoxic concentration. V-165 was dinucleotide CA immediately upstream of the cleavage
equally active against virus strains that were resistant site is critical for enzymatic activity. In the first step of
toward inhibitors of viral entry or reverse transcriptase. the integration reaction, termed 3 end processing, the
In combination regimens in cell culture, V-165 acted dinucleotide pGT is removed from each 3 end, to pro-
subsynergistically with zidovudine or nelfinavir and syn- duce new 3 hydroxyl ends (CA-3-OH). This reaction
ergistically with nevirapine. V-165 inhibited both reverse occurs in the cytoplasm, within a large viral nucleo-
transcriptase and integrase activities in enzymatic assays protein complex, the preintegration complex (PIC) [7].
at micromolar concentrations, but only a close correla- After entering the nucleus, the processed viral double-
tion was found between the anti-HIV activity observed stranded DNA is joined to host target DNA. The joining
in cell culture and the inhibitory activity in the integrase reaction includes a coupled 5 bp staggered cleavage
strand transfer assays. Time-of-addition experiments in- of the target host DNA and the ligation of processed
dicated that V-165 interfered with the viral replication CA-3-OH viral DNA ends to the 5 phosphate ends of
cycle at a time point coinciding with integration. Quanti- the target DNA. Repair of the remaining gaps, although
tative Alu-PCR corroborated that the anti-HIV activity not understood at this time, is probably accomplished
of V-165 is based upon the inhibition of proviral DNA by host cell DNA repair enzymes, although retroviral
integration. enzymes have been implicated as well [8–10].
Conclusions: Based on their mode of action, which is Establishment of high-throughput microtiter plate
different from that of clinically approved anti-HIV drugs, assays [11, 12] facilitated the discovery of IN inhibitors
by screening chemical libraries. Although evaluation ofPDPs are good candidates for further development into
IN inhibitors in rather cumbersome preintegration com-new drugs and to be included in future combination
plex assays has been discussed [13], IN inhibition isregimens.
typically assessed in oligonucleotide-based assays us-
ing LTR mimics to evaluate both processing and joining
reactions in vitro [14, 15]. Different classes of HIV-1 IN3 Correspondence: zeger.debyser@uz.kuleuven.ac.be
4 These authors contributed equally to this work. inhibitors have been reported (for reviews, see [16–18]):
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(1) nucleotides and analogs, (2) hydroxylated aromatic
compounds, (3) DNA-interacting agents, and (4) pep-
tides and antibodies. However, most of these com-
pounds did not exhibit antiviral activity in cell culture.
For most IN inhibitors that show an antiviral effect, it
has not been unambiguously demonstrated that the in-
tegration step is targeted. On the contrary, both zintevir
and L-chicoric acid, two compounds reported to target
integrase, were recently unmasked as inhibitors of viral
adsorption. Zintevir, a guanosine quartet (G-quartet)-
forming oligonucleotide is a potent inhibitor of HIV repli-
cation in cell culture [19]. Although Zintevir inhibits HIV
IN activity in the nanomolar range, it has been clearly
shown by selecting and sequencing drug-resistant
strains that the antiviral activity in cell culture is primarily
due to the inhibition of viral entry [20, 21]. The dicaffeoyl
quinic acid and L-chicoric acid (L-CA) derivatives were
also reported to inhibit HIV-1 IN in vitro and HIV-1 repli-
cation in cell culture [22]. An HIV-1 strain resistant to
L-chicoric acid was selected and a mutation mapped
in the IN gene (G140S) [23]. However, we have recently
selected HIV-1 strains that are resistant to L-CA and
contain mutations in gp120 and not in the integrase.
Figure 1. Structure of 5-(4-substituted-phenyl)-5H-pyrano[2,3-Recombination of the mutant gp120 gene into a wild-
d:-6,5-d]dipyrimidinestype background resulted in a virus strain resistant
to L-CA, indicating that L-CA does interfere with viral
entry [24].
The only authentic inhibitors of HIV-1 integration re-Many polyhydroxylated aromatic compounds have
ported so far are the diketo acids (DKA) that inhibit HIV-1been reported as inhibitors of HIV-1 IN in vitro. Flavones
replication at micromolar concentrations through a spe-[25], tyrphostins [26], lignans [27], anthraquinones [13],
cific inhibition of the DNA strand transfer step [41]. Se-and biscatechols [27, 28] are all characterized by two
lected DKA-resistant strains were shown to carry muta-vicinal hydroxyl groups on an aromatic ring. Hydroxy-
tions in the integrase gene. When these mutations werelated aromatics that do not contain ortho hydroxyls but
introduced in integrase, they conferred partial resis-inhibit IN activity have been reported as well. Curcumin
tance to the drugs. Another diketo derivative, 5-CITEP,[29], coumermycin A1, and biscoumarins [30] belong to
was recently cocrystallized with the catalytic core ofthis class. Using molecular modeling, pharmacophores
HIV-1 integrase [42]. The compound bound to the activehave been identified among the known hydroxylated
site and was reported to inhibit integrase activity ataromatic inhibitors that may lead to discovery of novel
micromolar concentration. Recently, more potent con-lead compounds [31]. Antiviral potency of catechol-type
geners of diketo acids were synthesized that provedinhibitors in cell culture is however confounded by inher-
capable of inhibiting HIV-1 replication in the nanomolarent cellular toxicity.
range [43].Many DNA binding agents were found to inhibit HIV-1
Our general strategy for discovery of IN inhibitors con-IN, probably due to a nonspecific interaction with the
sists of evaluating original compounds in a semiauto-DNA binding domain of the enzyme. Intercalators and
mated cell culture-based test system for their potentialDNA groove binding compounds such as netropsin be-
to suppress replication of HIV-1 at noncytotoxic concen-long to this category [32–34]. DNA triplex-forming oligo-
trations. Next, selective inhibitors of HIV replication arenucleotides linked to an intercalating oxazolopyridocar-
tested for IN inhibition in oligonucleotide-based assays.bazole can act as U3-specific [35] or U5-specific [36]
Here we describe the anti-HIV activity of 5-(4-substi-LTR binding inhibitors of HIV-1 IN. A 30-mer peptide,
tuted-phenyl)-5H-pyrano[2,3-d:-6,5-d]dipyrimidinescorresponding to amino acids 147 through 175 of HIV-1
(PDPs) in cell culture and demonstrate that the com-IN, was shown to inhibit IN activity at a millimolar con-
pounds act by inhibiting viral integration. Based on thecentration [37]. Intracellular expression of single-chain
mode of action that is different from that of clinicallyvariable fragments against IN domains inhibit early
approved anti-HIV drugs, PDPs are good candidates forstages of the viral replication cycle [38], and this could
further development into new drugs to be included inlead to a gene therapeutic approach.
potent drug combination therapy regimens.Some other classes of compounds that show weak
antiviral activity have been reported more recently. Styr-
Resultsylquinolines inhibit 3 processing and display moderate
antiviral activity [39]. Thiazolothiazepine inhibitors dis-
Inhibition of HIV and SIV Replication in Cell Cultureplay weak inhibitory activity of integrase activity and of
We evaluated a series of 5-(4-substituted-phenyl)-5H-viral replication [40]. For both classes of compounds,
pyrano[2,3-d:-6,5-d]dipyrimidines (Figure 1, Table 1) forcorroboration of the antiviral target in cell culture is
awaited for. their potential to inhibit the replication of HIV and SIV
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Table 1. Antiretroviral Activity and Cytotoxicity of 5H-pyrano[2,3-d:-6,5-d]dipyrimidines
EC50a (M)
HIV-1 HIV-2 SIV
Compound IIIB L1 ROD EHO MAC251 CC50b (M)
V-98 276 276 276 276 276 276
V-99 17.5 17.5 17.5 17.5 17.5 17.5
V-100 170  45 116.3  30.5 383 169.3  27 194.2 383
V-101 313 313 313 313 313 313
V-102 273  38 309 309 309 309 309
V-103 347 347 347 347 347 347
V-104 56.8  30 101  32 137 137 100.4 137
V-165 8.9  0.7 3.7  1.8 29.8  6.2 3.7  0.1 5.5  0.9 120.6
V-545 188.9 — 188.9 — — 188.9
L-708,906 5.5  2.4 60.1  10.7 62.1  35.0 54.1  12.4 6.1  2.2 88.3  42.1
Nevirapine 0.07  0.02 0.10  0.01 97.6 97.6 97.6 97.6
All data represent mean values and standard deviations for at least two separate experiments.
a 50% effective concentration, or concentration required to inhibit the viral cytopathic effect by 50% in cell culture.
b 50% cytotoxic concentration, or concentration that reduces by 50% the viability of MT-4 cells.
in a cell culture model for acute infection. The cytotoxic- with thiol functions at positions 2 and 8 and a nitro
substituent in para on the phenyl group, has the highestity of the compounds was determined in parallel. The
antiviral activity and cytotoxicity data are shown in Table selectivity against HIV replication in MT-4 cells. From
this structure-activity relationship (SAR) analysis, it1. Selected compounds were tested against HIV-1(IIIB),
two HIV-2 strains (ROD and EHO), and SIV(MAC251) should be clear that other derivatives, carrying X, Y, Z
substituents, could offer interesting antiretroviral prop-in MT-4 cells. Four derivatives were active against the
replication of HIV-1(IIIB): V-100, V-102, V-104, and V-165. erties.
The most active congener of this series, V-165 or 5-(4-
nitrophenyl)-2,8-dithiol-4,6-dihydroxy-5H-pyrano[2, Inhibitory Activity of PDP against Drug-Resistant
HIV-1 Strains3-d:-6,5-d]dipyrimidine, was active at a 50% effective
concentration (EC50) of 8.9 M. V-165 was also active The antiviral activity of the compounds was tested
against various drug-resistant HIV-1 strains (Tables 2against HIV-1(NL4.3 and L1), HIV-2(ROD and EHO), and
SIV(MAC251), at EC50 values ranging from 3.7 to 30 M. and 3). Whereas L-CA was inactive against HIV-1 strains
that are resistant to the viral entry antagonists dextranThe integrase inhibitor L-708,906 inhibited the replica-
tion of these virus strains at comparable concentrations sulfate or bicyclam AMD3100, L-708,906 and V-165 re-
tained their activity (Table 2). We observed a maximalranging from 5.5 to 62 M. The nonnucleoside reverse
transcriptase inhibitor nevirapine, in contrast, did not 2-fold reduction in inhibitory potency of V-165 and
L-708,906 against a NNRTI-resistant HIV-1 strain, whereasinhibit the replication of HIV-2(ROD and EHO) and SIV
(MAC251) at concentrations up to about 100 M in MT-4 nevirapine lost all activity (Table 3). The NRTI-resistant
strain was resistant to AZT but remained sensitive tocells (Table 1). The 50% cytotoxic concentration (CC50)
of V-165 in MT-4 cells, 121 M, was approximately 14- inhibition by nevirapine, V-165, and L-708,906 (Table 3).
fold higher than its EC50 value against the replication
of HIV-1(IIIB). Approximately the same cytotoxicity was Mechanism of Action Studies
Time of Interventionobserved for the DKA L-708,906 (CC50, 88.3 M), at a
concentration 16-fold higher than the EC50 for inhibition A time-of-addition (TOA) experiment was carried out
to investigate which step of the replicative cycle wasof replication of HIV-1(IIIB).
inhibited by V-165. Briefly, this experiment determines
Structure-Activity Relationship for PDPs
The structures of the compounds used in this study are
Table 2. Antiviral Activity of V-165 against HIV Strains Resistantshown in Figure 1. All the molecules belong to the 5-(4-
to Entry Inhibitorssubstituted-phenyl)-5H-pyrano[2,3-d:-6, 5-d]dipyrimid-
ines. The molecules differ in the substituents at positions EC50a (M)
2 and 8 (X), 4 and 6 (Y), and in the parasubstituent
Compound NL4.3 WT NL4.3 DSres NL4.3 AMD3100reson the phenyl group (Z). The antiviral activity is clearly
dependent on the X, Y, and Z substituents. The mole- L-CA 12.7  8.5 115 115
L-708,906 10.1  5.2 8.0  1.7 8.4  0.2cules with a sulfhydryl function at the positions 2 and
V-165 14.7  9.7 19.4  1.4 19.1  1.48, namely, V-104 and V-165, show more pronounced
antiviral activity than the congeners with hydroxyl sub- Data represent mean average values SD for two to three indepen-
dent experiments. The strain NL4.3 DSres is resistant against DS5000;stituents at the same positions. Methylation of the sulfur
NL4.3 AMD3100res is resistant against AMD3100.atoms in V-545 led to a total loss in activity. The parasub-
a 50% effective concentration, or concentration required to achievestituent on the 5-phenyl group is important for antiviral
50% inhibition of the cytopathic effect of the HIV-1 strain tested.
activity (compare V-104 with V-165). Compound V-165,
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since TOA experiments only reveal the last step targetedTable 3. Antiviral Activity of V-165 against HIV Strains Resistant
to RT Inhibitors during the viral replication process.
Combined Inhibitory Effects of V-165EC50a (M)
with Approved HIV-1 Inhibitors
Compound NL4.3 WT NNRTIres NRTIres The antiviral effect of V-165 was tested in combination
with the nucleoside reverse transcriptase inhibitor zido-AZT 0.005  0.002 0.003  0.001 7.5
Nevirapine 0.060  0.007 15 0.01  0.001 vudine (AZT), the nonnucleoside RT inhibitor nevirapine,
L-708,906 10.1  5.2 19.3  14.7 5.2  1.2 or with the protease inhibitor nelfinavir. The combined
V-165 14.7  9.7 33.5  15.7 15.1  9.2 inhibitory effects on HIV-1-induced CPE were evaluated
by the isobologram method. The added fractional inhibi-Data represent mean values  SD for two to three independent
experiments. The strain NNRTIres contains the mutations K103N and tory concentration for zidovudine and V-165 (FICzidovudine 
Y181C in RT. The strain NRTIres contains the following mutations in FICV-165) and FICnelfinavir  FICV-165 values fell between 0.5
RT: A62V, 69SS, K70R, E79K, V118I, M184V, E203K, L210W, and and 1, which means that the combinations were subsyn-
T215Y.
ergistic. All added FICnevirapine  FICV-165 values fell belowa 50% effective concentration, or concentration required to achieve
0.5, implying a synergistic combination (Figure S1 in50% inhibition of the cytopathic effect of the HIV-1 strain tested.
the Supplementary Material available with this article
online).
No Inhibition of HIV-1 Production by Persistentlyhow long the addition of an anti-HIV compound can be
Infected Cellspostponed within the viral replication cycle before losing
When V-165 was evaluated for its inhibitory effect onits antiviral activity. Virus was added at a high multiplicity
virus production by chronically HIV-1(IIIB)-infected HUT-of infection (m.o.i. 0.5) to synchronize all steps of viral
78 cells, we noticed no inhibitory effect on the releasereplication. Reference compounds with a known mode
of infectious virus at 124 M. Similar results have beenof action were included. Dextran sulfate, a polyanion,
reported for L-708,906 and L-731,988 in MOLT cellsis known to interfere with binding of the virus to the cell.
chronically infected with HIV-1(IIIB) [41]. At concentra-The nucleoside analog AZT inhibits the reverse tran-
tions higher than 124 M, V-165 proved to be toxicscription process. Ritonavir is an inhibitor of the proteo-
for HIV-1(IIIB)-infected HUT-78 cells (data not shown).lytic cleavage. Addition of these inhibitors can be de-
Ritonavir reduced the HIV-1 yield from the persistentlylayed for 0, 4–5, and 18–19 hr after infection, respectively
infected cells by 2 log at 3 M without any detectable(Figure 2). The known strand transfer inhibitor, the diketo
cytotoxicity (data not shown).acid L-708,906, lost its activity when added more than
Inhibition of Lentiviral Vector-Mediated9 hr beyond infection. Although V-165 lost already some
Transductionactivity when added more than 4 hr after infection, a
To corroborate the interference of the inhibitor with thecomplete loss of activity was only observed when addi-
tion was postponed for more than 9 hr (Figure 2). How- HIV reverse transcription and/or integration steps, sin-
ever, these experiments cannot exclude the fact that gle-round infections of 293T cells were done using
V-165 would interact with reverse transcription as well, HIV-1-derived vectors pseudotyped with the VSV-G en-
velope and carrying luciferase as a reporter gene [44].
In this assay, a decrease in luciferase activity is a mea-
sure for the inhibition of the early HIV replication steps.
Inhibition of transduction was obtained with V-165 at an
average EC50 value of 17 M (data not shown). The con-
trol reverse transcriptase inhibitors AZT and -APA in-
hibited lentiviral transduction at an EC50 value of 49 nM
and 5 nM, respectively. The lack of gp120 in the viral
particle excludes HIV-type viral entry as a target. V-165
inhibited the transduction by a second-generation vec-
tor that lacked the accessory factors nef, vif, vpr, and
vpu [45] to the same extent (data not shown), excluding
a major role for these HIV proteins in the antiviral mecha-
nism. These assays corroborate HIV-1 reverse transcrip-
tion and integration as the potential targets for the antivi-
ral effect of the compound in cell culture.
Inhibition of HIV Reverse Transcriptase Activity
Inhibition of HIV-1 reverse transcriptase enzymatic ac-
tivity by the most active PDPs was evaluated (Table S1).
The most potent compound of the PDP series, V-165,
Figure 2. Time-of-Addition Experiment inhibited HIV RT activity, using different template prim-
MT-4 cells were infected with HIV-1(IIIB) at a multiplicity of infection ers, i.e., poly(rC).oligo(dG) and poly(rA).oligo(dT), at an
of 0.5, and the test compounds were added at different time points IC50 value of 4.8 and 24.6M, respectively. A weak corre-postinfection. Viral p24 Ag production was determined at 31 hr
lation between the antiretroviral activity in cell culturepostinfection. Control, gray circle; dextran sulfate (20 M), filled
and the inhibitory activity in the RT assays was observedtriangle; AZT (1.9 M), gray square; ritonavir (2.8 M), filled square;
L-708,906 (250 M), open triangle; V-165 (250 M), cross. (r2  0.08 and 0.35, respectively).
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PDP derivatives (V-99, V-100, V-102, V-103, V-104,
V-165) inhibited the 3 processing and the overall inte-
gration reaction. V-104 and V-165 were the most potent
congeners, with IC50 values between 0.3 and 1 M. In
a separate assay, DNA strand transfer by preformed
complexes of integrase and processed DNA was mea-
sured (Table 4). V-165 has a strong inhibitory effect on
the DNA strand transfer reaction, with an IC50 value of
16.1 M, whereas V-100, V-104, and V-961 were only
weakly active. A strong correlation between the antiret-
roviral activity observed in cell culture and the inhibitory
activity in the integrase assays was observed. The best
correlation was obtained between the inhibitory potency
in cell culture and in the strand transfer assay (linear
regression, r2  0.998). Binding of integrase to a specific
immobilized double-stranded oligonucleotide can be
measured with biosensor technology [20]. After preincu-
bation of integrase with 93 M of V-165, the binding of
integrase to the DNA was completely abolished. Next,
we verified whether V-165 was capable of inhibiting the
cleavage reaction of integrase in preformed complexes
[20]. We determined the rate constant for production of
the cleaved product to be 0.152  0.038 min1. In the
presence of 50 M of V-165, a similar kcat value was
obtained (0.147  0.025 min1), ruling out that V-165
directly affects the catalysis of 3 processing (Figure
S2). It follows that the inhibition of 3 processing (Figure
Figure 3. Inhibition of HIV-1 Integrase Activity by V-165
3) is due to inhibition of integrase-DNA complex for-
The overall integration reaction (60 min) was carried out in the ab- mation.
sence (lanes 2 and 10) or in the presence of decreasing amounts
No Evidence for Intercalation of V-165of the DKA L-708,906 (lanes 3 through 9) or the PDP V-165 (lanes
into Double-Stranded DNA11 through 17). The concentrations of L-708,906 were 50 M (lane
3), 16.7 M (lane 4), 5.56 M (lane 5), 1.85 M (lane 6), 0.62 M We verified whether the compounds intercalate in dou-
(lane 7), 0.21 M (lane 8), and 0.07 M (lane 9). The concentrations ble-stranded DNA. It is known that intercalators stabilize
of V-165 were 50 M (lane 11), 16.7 M (lane 12), 5.56 M (lane 13), the double helix by insertion between two consecutive
1.85 M (lane 14), 0.62 M (lane 15), 0.21 M (lane 16), and base pairs. This stabilization is reflected by an increase
0.07 M (lane 17). A negative control (no enzyme added) is shown
of the melting temperature (defined as the temperaturein lane 1.
where 50% of the double strand is dissociated in two
single strands) of the double strand. We used the dou-
Inhibition of HIV Integrase Activity ble-stranded DNA from the in vitro integration assay
Inhibition of 3 processing, DNA strand transfer, and the (INT1-INT2) at a fixed concentration of 1 M for each
overall integration reaction was measured in oligonucle- oligodeoxynucleotide. A serial dilution of V-165 (25→
otide-based assays [20] (Table 4 and Figure 3). Seven 5→1→0.2→0.04 and 0 M) was added to different cu-
vettes containing INT1-INT2. The temperature of the cu-
vettes was first gradually increased (0.2	C/min) fromTable 4. Inhibition of HIV-1 Integrase Activity by PDP
15	C to 80	C and then decreased at the same rate toCompounds
15	C, while monitoring the absorbance at 260 nm. TheIC50a (M)
melting point remained unaffected (59	C) in the pres-
Overall Strand ence of different concentrations of V-165 (data not
Compound 3 Processing Integration Transfer shown). This points against V-165 inhibiting integration
V-98 206.6 206.6 ND by merely stabilizing double-stranded DNA by interca-
V-99 74.0  38.5 25.0  4.5 ND lation.
V-100 22.4  6.4 34.6  11.3 782  242 Analysis of HIV Integration Using Real-Time PCR
V-101 250 250 ND
To assess whether the PDPs inhibit the integration stepV-102 208.0  82.2 298.3  7.7 1235
during HIV replication, DNA extracts of cells transducedV-103 143.7  81.3 143.1  25.8 ND
with HIV vectors in the absence or presence of V-165V-104 0.9  0.5 1.0  0.4 201.3  119.7
V-165 0.9  0.4 0.3  0.2 16.1  10.7 were analyzed by quantitative PCR (Figure 4). Transduc-
V-545 ND 202 ND tions in the presence of AZT or the diketo acid L-708,906
L-708,906 20.5  3.7 0.2  0.07 3.5  1.2 were done in parallel. Inhibition of vector transduction
at concentrations used was verified by FACS analysisData shown are mean values  SD for at least two different experi-
ments. ND, not determined. (Table S2). Inhibition by the diketo acid and V-165 was
a 50% inhibitory concentration, or concentration required to inhibit more pronounced after passaging of the cells. The time
50% of the activity of HIV-1 integrase in the different enzymatic course of production of late reverse transcripts (4A),
assays.
2-LTR circles (4B), or integrants (4C) was measured us-
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Figure 4. Analysis of HIV Integration by Quantitative PCR
293T cells were transduced with HIV-1 vectors at m.o.i.  10 in the absence of inhibitor (circle) or in the presence of 750 nM AZT (square),
25 M L-708,906 (triangle, top up), or 25 M V-165 (triangle, top down). At different time points after infection, DNA extracts were prepared
and analyzed by real-time PCR. Late reverse transcripts were quantified (A), as well as 2-LTR circles (B) and integrated proviral DNA (C). A
no-amplification control was run in parallel (circle, dashed line).
ing specific primers and probe. In the presence of 750 that were resistant toward inhibitors of viral entry or
nM AZT, reverse transcription and 2-LTR circle forma- reverse transcription. The same antiretroviral activity
tion are inhibited. As a result, no proviral DNA is inte- spectrum was observed for the known integrase inhibi-
grated. In the presence of 25 M L-708,906, there is a tor, the diketo acid L-708,906. Based on the inhibition
clear increase in 2-LTR circle formation, accompanied of HIV-1 vector-mediated transduction of 293T cells,
by a block in integration. These data are consistent with PDPs may be assumed to interact with the reverse tran-
an inhibition of the strand transfer step in the nucleus scription and/or integration process. Since the lentiviral
of the infected cell. In the presence of 25 M of V-165, vectors used are pseudotyped with the envelope of VSV
there was no inhibition of reverse transcription (Figure and since the compounds were inactive against VSV
4A), a moderate increase in 2-LTR circle formation (Fig- replication in cell culture (data not shown), the viral entry
ure 4B), and a clear inhibition of viral integration (Fig- step could be excluded as the antiviral target. HIV-1-
ure 4C). specific replication steps following integration are not
tested for in a single-round transduction experiment.
The viral accessory proteins Vpr, Vpu, Nef, and Vif wereDiscussion
not required for activity of PDP. In a Tat-dependent
transactivation assay, V-165 was found inactive (dataWe have identified a novel series of selective inhibitors
not shown).of HIV replication, the 5-(4-substituted-phenyl)-5H-
In enzymatic assays, PDPs inhibited both reversepyrano[2,3-d:-6,5-d]dipyrimidines (PDP), with a novel
transcription and integration reactions. For the activemode of action. The most potent congener, 5-(4-nitro-
congeners, a correlation was found between the inhibi-phenyl)-2,8-dithiol-4,6-dihydroxy-5H-pyrano[2,3-d:-6,
tory activity in cell culture and the inhibitory potency on5-d]dipyrimidine (V-165), inhibited the replication of dif-
the integrase reactions; in all experiments, 5-(4-ni-troferent HIV-1(NDK, NL4.3, and L1) strains, HIV-2(ROD and
phenyl)-2,8-dimercapto-4,6-dihydro-5H-pyrano[2,3-d:EHO), and SIV(MAC251), at EC50 values ranging from 3.7
-6,5-d]dipyrimidine (V-165) was the most potent deriva-to 30 M. V-165 inhibited the replication of HIV-1(IIIB) in
tive. The best correlation was observed in the strandMT-4 cells at a 50% effective concentration (EC50) of 8.9
transfer assay (r2  0.996). Addition of V-165 to double-M, which is almost 15-fold below its cytotoxic concen-
tration. Moreover, V-165 was active against virus strains stranded (ds)DNA did not affect the DNA melting tem-
Novel Class of Inhibitors of HIV Integration
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perature, ruling out the possibility that this compound, cell culture were unsuccessful so far. Still, the PDP se-
ries of compounds represents, next to diketo acids, onlywhich is also not fully planar, acts only as a typical
intercalator. Nevertheless, at this stage it cannot be ex- the second class of authentic inhibitors of HIV integra-
tion in cell culture. V-165 should therefore be consideredcluded that the planar moiety of PDP is involved in inter-
actions with dsDNA. as a lead compound for further chemical synthesis and
development of novel anti-HIV drugs to be included inLack of inhibition of virus production by persistently
infected cells by V-165 points to an antiviral target prior combination therapy regimens.
to or coinciding with integration. In TOA experiments,
Experimental ProceduresV-165 appeared to interfere with the viral replication
cycle at a moment following reverse transcription. A
Compounds
known RT inhibitor, AZT, lost its activity when added All PDP derivatives were obtained from Ampharm Inc. (Ramsey, NJ)
more than 4 hr postinfection; addition of V-165, in con- [47]. AZT was synthesized as previously described [48]. Tivirapine
trast, could be postponed for 8 hr. However, part of the (8-chloro-TIBO, R86183) and loviride (-APA R89439) were obtained
from Janssen Research Foundation (Beerse, Belgium). Nevirapineactivity was already lost at 4–5 hr. Addition of the diketo
(BI-RG587) was obtained from Boehringer Ingelheim (Ridgefield,acid L-708,906, a specific inhibitor of the DNA strand
CN). Saquinavir (Ro31-8959) was a gift of Dr. N. Roberts (Rochetransfer step in cell culture, could be delayed to 9 hr after
Products Limited, Welwyn Garden City, UK). Ritonavir (ABT538) was
infection. A possible explanation for the time difference kindly provided by J.M. Leonard, Abbott laboratories (Abbott Park,
between PDP and DKA is the inhibitory effect of PDP IL). Dextran sulfate with an average molecular weight of 5000 was
on integrase-DNA complex formation that is preceding purchased from Sigma. Nelfinavir (AG 1343) was a gift from Agouron
Pharmaceuticals (La Jolla, CA). The diketo acid L-708,906 [41] wasthe DNA strand transfer step. From these data, it cannot
kindly provided by Dr. N. Neamati and Dr. T.R. Burke (Nationalbe excluded that the PDPs also interfere with reverse
Institutes of Health, Bethesda, MD).transcription. The setup of a typical TOA experiment
allows the identification of the last susceptible replica- Viruses, Cells, Antiviral Activity, and Cytoxicity Assays
tion step. PDPs may well be inhibitors of both reverse Viruses, cells, and virological assays were as described previously
transcription and integration. It should be noted that [24] or as explained in the Supplementary Material.
reverse transcription and integration are coupled and
Time-of-Addition Experimentspartially synchronous during retroviral replication. In the
MT-4 cells were infected with HIV-1(IIIB) at an m.o.i. of 0.5, and thepreintegration complex, integrase binds to the first frag-
compounds were added at different time points after infection (0,
ment of cDNA, well before the reverse transcription pro- 1, 2, 3...8, 9, 24, and 25 hr). Viral p24 antigen production was deter-
cess is completed. A physical interaction between the mined at 31 hr postinfection (HIV-1 p24 Core Profile ELISA, DuPont,
RT and the IN of HIV-1 has been demonstrated [46]. If Dreieich, Germany). The reference compounds (dextran sulfate,
AZT, and ritonavir) were added at a standardized concentrationPDPs interfere with structural alterations of the nascent
corresponding to 100 times the EC50 value, determined at an m.o.i.cDNA, they may block both reverse transcription and
of 0.01. V-165 and the diketo acid L-708,906 were both added atintegration, at least in enzymatic assays. To the extent
250 M.
that PDPs inhibit HIV-1 RT activity, their mechanism of
interaction is different from that of previously reported Reverse Transcriptase Assay
RT inhibitors (nucleoside and nonnucleoside RT inhib- The procedures to obtain virion-derived enzyme and to assay for
reverse transcriptase activity have been described before [49].itors).
Poly(rC).oligo(dG) and poly (rA).oligo(dT) were used as templateTo discriminate between reverse transcription and in-
primers, and 8-[3H]-dGTP and [3H]-dTTP were used as radiolabeledtegration as the major antiviral target in cell culture, a
substrates. The final 8-[3H]-dGTP and [3H]-dTTP concentrations in
series of quantitative PCRs was carried out on DNA the reaction mixture were 2.5 M. Recombinant HIV-1 RT (HXB2)
extracted from cells transduced with HIV-1 vectors in was obtained as previously described [50].
the absence or presence of V-165. In the presence of
Integration ReactionsV-165 there was no inhibition of total DNA synthesis, a
Preparation of HIV-1 recombinant integrase and integrase substratesmall increase in 2-LTR circle formation, and a clear
and target DNA was as described [20]. The 3 processing, overallinhibition of integration. The diketo acid L-708,906
integration, strand transfer, and kinetic 3 cleavage assays were as
showed a similar profile, although the increase in 2-LTR described previously, with minor modifications [20, 51].
circles was more pronounced. Possibly, this relates to
the inhibitory effect of V-165 on the DNA-integrase com- HIV-1 Integrase Binding Experiment
Binding experiments were carried out using biosensor technologyplex formation that takes place in the cytoplasm of the
on BIAcore2000 (Biacore) and sensor chips SA with preimmobi-infected cell and may be required for efficient nuclear
lized streptavidin as described previously [20].import. L-708,906, in contrast, behaved as a specific
inhibitor of the DNA strand transfer reaction.
Lentiviral Vector Transduction Assay
HIV-1-derived vector particles, pseudotyped with the envelope of
vesicular stomatitis virus (VSV), were produced by transfecting 293T
Conclusions cells with three plasmids as described previously [44]. The plasmids
used were a packaging plasmid pCMV
R8.2 or pCMV
R8.91, aWe spent much effort to corroborate the antiviral target
plasmid encoding the envelope of vesicular stomatitis virus (pMDG),of PDPs in cell culture, since authenticity of integrase
and a plasmid encoding a reporter gene flanked by two long terminalinhibition and avoidance of mistaken identity is a prereq-
repeats (LTRs) (pHR-CMVluciferase) [45]. The plasmids were ob-uisite for delineating the appropriate structure-activity
tained through the European gene Vector Database and Repository
relationship, which in turn is a prerequisite for identifying (EGDR) (Dr. O. Danos, Ge´ne´thon, France) from Dr. D. Trono (Geneva).
the appropriate lead compound(s) for clinical develop- Inhibitors were evaluated in 96-well plates. Per well, 2000 pg of
vector and 2 g/ml polybrene were added to a confluent monolayerment. Attempts to select V-165-resistant HIV strains in
Current Biology
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of 293T cells grown in 100l of DMEM/1% FCS. Inhibitors at different Hughes, and H. Varmus, eds. (Cold Spring Harbor, NY: Cold
Spring Harbor Laboratory Press) pp. 161–203.concentrations were included. At 48 hr after transfection, cells were
lysed, and luciferase activity was measured in the LumicountTM 7. Miller, M.D., Farnet, C.M., and Bushman, F.D. (1997). Human
immunodeficiency virus type 1 preintegration complexes: stud-(Packard, Meriden, CT), using the Luciferase Assay SystemTM (Pro-
mega Benelux, Leiden, The Netherlands). Normalization for cell ies of organization and composition. J. Virol. 71, 5382–5390.
8. Chow, S.A., Vincent, K.A., Ellison, V., and Brown, P.O. (1992).count was done by determining protein concentration using BCATM
Protein Assay Reagent (Pierce, IL). Reversal of integration and DNA splicing mediated by integrase
of HIV. Science 255, 723–726.
9. Yoder, K.E., and Bushman, F.D. (2000). Repair of gaps in retrovi-Quantification of DNA Species in Vector-Transduced
ral DNA integration intermediates. J. Virol. 74, 11191–11200.Cells Using Real-Time PCR
10. Brin, E., Yi, J., Skalka, A.M., and Leis, J. (2000). Modeling the late293T cells were transduced with HIV-1 vectors at m.o.i. 10. Trans-
steps in HIV-1 retroviral integrase-catalyzed DNA integration. J.ductions were carried out in a 24-well plate containing 1  105 cells
Biol. Chem. 275, 39287–39295.per well. The inhibitors were added prior to infection. At different
11. Vink, C., Banks, M., Bethell, R., and Plasterk, R.H.A. (1994).time points after infection, cells were lysed by addition of a solution
A high-throughput, non-radioactive microtiter plate assay forof 0.5% SDS with 100 mM NaCl, 10 mM TrisCl (pH 8.0), 25 mM
activity of the HIV integrase protein. Nucleic Acids Res. 22,EDTA (pH 8.0), and 0.2 mg/ml proteinase K, and incubated for 6 hr
2176–2177.at 56	C. After lysis, DNA was extracted with phenol/chloroform, and
12. Hazuda, D.J., Hastings, J.C., Wolfe, A.L., and Emini, E.A. (1994).the DNA concentration was determined photospectrometrically. For
A novel assay for the DNA strand-transfer reaction of HIV-1each DNA species, a specific TaqMan probe and primer set was
integrase. Nucleic Acids Res. 22, 1121–1122.designed [52]. Reactions were analyzed using the ABI Prism 7700
13. Farnet, C.M., Wang, B., Lipford, J.R., and Bushman, F.D. (1996).sequence detection system (Applied Biosystems, Lennik, Belgium).
Differential inhibition of HIV-1 preintegration complexes and
purified integrase protein by small molecules. Proc. Natl. Acad.Determination of DNA Melting Temperature
Sci. USA 93, 9742–9747.Melting curves of INT1-INT2 DNA duplex in the presence of various
14. Sherman, P.A., and Fyfe, J.A. (1990). Human immunodeficiencyconcentrations of V-165 were determined with a Varian CARY 300
virus integration protein expressed in Escherichia coli pos-Bio Spectrophotometer.
sesses selective DNA cleavage activity. Proc. Natl. Acad. Sci.
USA 87, 5119–5123.Supplementary Material
15. Bushman, F.D., and Craigie, R. (1991). Activities of human immu-Supplementary Material including Supplementary Experimental Pro-
nodeficiency virus (HIV) integration protein in vitro: specificcedures, figures (Figure S1, Inhibition of HIV Replication by Combi-
cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USAnations of Inhibitors; Figure S2, No Inhibition of the Kinetic Cleavage
88, 1339–1343.Reaction by V-165), and tables (Table S1, Inhibition of HIV-1 Reverse
16. Pommier, Y., Marchand, C., and Neamati, N. (2000). RetroviralTranscriptase Activity by PDPs and Reference Compounds Using
integrase inhibitors year 2000: update and perspectives. Antivi-Different Template Primers; Table S2, Inhibition of HIV-1 Vector
ral Res. 47, 139–148.Transduction) can be found online at http://images.cellpress.com/
17. Neamati, N., Marchand, C., and Pommier, Y. (2000). HIV-1 integ-supmat/supmatin.htm.
rase inhibitors: past, present, and future. Adv. Pharmacol. 49,
147–165.
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